A single-arm, open-label, phase IV study investigating the combination of ribociclib and standard endocrine therapy to discover and validate molecular and non-molecular biomarkers predictive of drug response and resistance.
Breast cancer is a malignant disease of the mammary gland tissue that can be treated with hormone therapy if hormone receptors are present on the surface of the cancer cells. Ribociclib is a drug that can enhance the effects of hormone therapy. It is already approved. The aim of the CAPTOR-BC study is to obtain even more data on the effectiveness of hormone therapy in combination with ribociclib. Women aged 18 years and older with locally advanced or metastatic, hormone receptor-positive, and HER2-negative breast cancer are eligible to participate in this study.
